Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BLM | P54132 | 2/20 | 0.98 |
| ▸ | PMP22 | Q01453 | 2/20 | 0.98 |
| ▸ | LMNA | P02545 | 2/20 | 0.98 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.98 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | TSHR | P16473 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.44 |
| ▸ | GSR | P00390 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | PDE4A | P27815 | 1/20 | 0.34 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.34 |
| ▸ | TKT | P29401 | 5/20 | 0.34 |
| ▸ | EGFR | P00533 | 1/20 | 0.34 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Nimustine SCHEMBL23301409 | 0.99 | BLM (1.00) | BLMPMP22LMNANFKB1ALDH1A1 | |
| Nimustine SCHEMBL8414 | 0.99 | BLM (1.00) | BLMPMP22LMNANFKB1ALDH1A1 | |
| Nimustine SCHEMBL98303 | 0.98 | BLM (0.98) | BLMPMP22LMNANFKB1ALDH1A1 | |
| Nimustine SCHEMBL1649545 | 0.98 | BLM (0.98) | BLMPMP22LMNANFKB1ALDH1A1 | |
| Nimustine SCHEMBL1649348 | 0.97 | BLM (0.96) | BLMPMP22LMNANFKB1ALDH1A1 | |
| Nimustine SCHEMBL1580335 | 0.95 | BLM (0.92) | BLMPMP22LMNANFKB1ALDH1A1 | |
| Nimustine SCHEMBL5886061 | 0.88 | BLM (0.80) | BLMPMP22LMNANFKB1ALDH1A1 | |
| SCHEMBL25299723 | 0.87 | LMNA (0.79) | BLMPMP22LMNANFKB1TKT | |
| SCHEMBL17524414 | 0.87 | BLM (0.79) | BLMPMP22LMNANFKB1ALDH1A1 | |
| SCHEMBL6541875 | 0.82 | LMNA (0.71) | BLMPMP22LMNANFKB1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8962623-B2 | Aminopyrazine compounds | LOCUS PHARMACEUTICALS, INC. (US) | 2015-02-24 | — | — | US | disclosed |
| EP-2424368-B1 | PYRROLOTRIAZINE COMPOUNDS | LOCUS PHARMACEUTICALS INC (US) | 2014-12-31 | — | — | EP | disclosed |
| US-20140187529-A1 | AMINOPYRAZINE COMPOUNDS | LOCUS PHARMACEUTICALS, INC. (US) | 2014-07-03 | — | — | US | disclosed |
| US-8765754-B2 | Pyrrolotriazine compounds | LOCUS PHARMACEUTICALS, INC. (US) | 2014-07-01 | — | — | US | disclosed |
| US-8507545-B2 | Cytotoxic T cell activator comprising EP4 agonist | NATIONAL UNIVERSITY CORPORATION, HAMAMATSU UNIVERSITY SCHOOL OF MEDICINE (JP) | 2013-08-13 | — | — | US | disclosed |
| WO-2012121939-A2 | AMINOPYRAZINE COMPOUNDS | LOCUS PHARMACEUTICALS, INC. (US) | 2012-09-13 | — | — | WO | disclosed |
| US-20120232054-A1 | PYRROLOTRIAZINE COMPOUNDS | LOCUS PHARMACEUTICALS, INC. (US) | 2012-09-13 | — | — | US | disclosed |
| EP-2424368-A1 | PYRROLOTRIAZINE COMPOUNDS | Locus Pharmaceuticals, Inc. (US) | 2012-03-07 | — | — | EP | disclosed |
| WO-2010126960-A1 | PYRROLOTRIAZINE COMPOUNDS | LOCUS PHARMACEUTICALS, INC. (US) | 2010-11-04 | — | — | WO | disclosed |
| US-20100216689-A1 | CYTOTOXIC T CELL ACTIVATOR COMPRISING EP4 AGONIST | ONO PHARMACEUTICAL CO., LTD. (JP) | 2010-08-26 | — | — | US | disclosed |
| CN-101686985-A | Cytotoxic t cell activator comprising ep4 agonist | NAT UNIV CORP HAMAMATSU | 2010-03-31 | — | — | CN | disclosed |
| EP-2147672-A1 | CYTOTOXIC T CELL ACTIVATOR COMPRISING EP4 AGONIST | Nat. University Corp. Hamamatsu University School of Medicine (JP) | 2010-01-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140187529-A1 | AMINOPYRAZINE COMPOUNDS | ITK, IL4I1, IL5 | BLM 4648/4885PMP22 4152/4885LMNA 3413/4885 |
| US-20100216689-A1 | CYTOTOXIC T CELL ACTIVATOR COMPRISING EP4 AGONIST | CD4, PTGER4, LTB4R | BLM 4657/4885PMP22 3676/4885LMNA 4586/4885 |
| US-20120232054-A1 | PYRROLOTRIAZINE COMPOUNDS | BTK, SYK, ZAP70 | BLM 3659/4885PMP22 959/4885LMNA 3271/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.